Y Intercept Hong Kong Ltd Buys 52,414 Shares of Viridian Therapeutics, Inc. $VRDN

Y Intercept Hong Kong Ltd increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 430.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 64,594 shares of the company’s stock after purchasing an additional 52,414 shares during the period. Y Intercept Hong Kong Ltd owned approximately 0.08% of Viridian Therapeutics worth $1,394,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in VRDN. Farther Finance Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock valued at $42,000 after purchasing an additional 1,491 shares in the last quarter. Sei Investments Co. acquired a new stake in Viridian Therapeutics in the 2nd quarter valued at approximately $147,000. Creative Planning bought a new stake in Viridian Therapeutics in the 2nd quarter valued at approximately $179,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Viridian Therapeutics during the 2nd quarter worth approximately $180,000. Finally, Envestnet Asset Management Inc. bought a new position in shares of Viridian Therapeutics during the 2nd quarter worth approximately $187,000.

Viridian Therapeutics Stock Performance

NASDAQ VRDN opened at $33.00 on Friday. The company has a current ratio of 11.28, a quick ratio of 11.28 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average price is $32.11 and its two-hundred day moving average price is $24.71. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $34.29. The firm has a market capitalization of $3.15 billion, a P/E ratio of -10.93 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. The company had revenue of $70.57 million during the quarter, compared to the consensus estimate of $16.21 million. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The company’s revenue for the quarter was up 81993.0% on a year-over-year basis. As a group, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on VRDN. Wall Street Zen upgraded shares of Viridian Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, January 21st. Truist Financial cut their price target on shares of Viridian Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Wedbush increased their price objective on shares of Viridian Therapeutics from $42.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Finally, Royal Bank Of Canada raised their price objective on Viridian Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.43.

Insider Buying and Selling

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 2,272 shares of the business’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.58% of the company’s stock.

About Viridian Therapeutics

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.